Gitnux/Report 2026

Biomanufacturing Industry Statistics

The U.S. biomanufacturing value added reached $438.8B in the latest available NIST estimate (2021), explore the figures behind growth, companies and trends for 2026.
25Statistics
30Sources
5Sections
1Visuals
16mRead
Biomanufacturing Industry Statistics
How this report is researched
01Editorial Scope

Before any source is gathered, an editor locks the question, what qualifies, and how the piece will be judged.

02Source Research

Search agents collect the source set and pull each data point out with its provenance attached.

Read our full methodology →

Search agents attach provenance to every extracted figure.

Next review: within 38 days

01 Industry overview

The biomanufacturing industry at a glance

U.S. biological-product manufacturing employed 46,936 people in 2025, up 15.8% from 2021, while broader biomanufacturing value added was $438.8 billion in the latest available NIST estimate.

46,936[4]
U.S. biomanufacturing jobs, 2025
15.8%[4]
Employment growth, 2021–2025
$438.8B[13]
U.S. biomanufacturing value added
12.84%[3]
Digital biomanufacturing CAGR, 2026–2034
Market size
The latest broad U.S. estimate found $438.8 billion in direct biomanufacturing value added, with an additional $925.0 billion in indirect supply-chain and other value added, bringing the total to $1.364 trillion. This is the latest available NIST estimate and refers to 2021 economic activity.[13]
Forecast & CAGR
The narrower global digital-biomanufacturing market was valued at $22.44 billion in 2025 and is projected to reach $66.14 billion by 2034, implying a 12.84% CAGR from 2026 to 2034. The segment includes manufacturing-execution software, automation, digital twins, analytics and related services.[3]
Market share & regions
Global biomanufacturing capacity totaled 6,692 kL in 2024, including 2,467 kL in Europe, 2,340 kL in North America and 1,885 kL in Asia. On this capacity measure, Europe represented about 36.9%, North America 35.0% and Asia 28.2%.
Segmentation
The focused U.S. industry proxy is NAICS 325414, biological product manufacturing excluding diagnostics. It covers biologic medicines such as vaccines, therapeutic proteins, monoclonal antibodies, and blood- and plasma-derived therapies, while some cell and gene therapy, mRNA, viral-vector, fill-finish and multiproduct operations may be classified elsewhere.[4]
Key players & concentration
U.S. employment is geographically concentrated: 77% of the 46,936 biological-product-manufacturing jobs in 2025 were located in 12 states, although 45 states had some employment in the sector. Major biopharmaceutical manufacturers and contract manufacturers compete across process development, commercial production, fill-finish and specialized modalities.[4]
Pricing
Labor costs are a major pricing variable: a 2025 BIO submission cited U.S. entry-level bioprocess-engineer salaries of $75,000–$95,000, compared with $15,000–$21,000 in China. The same source estimated that producing one kilogram of a protein therapeutic can require up to 30,000 kilograms of water, adding significant operating-cost pressure.[4]
Trends, drivers & challenges
Demand is being supported by biologic medicines, contract development and manufacturing, advanced production systems and efforts to diversify domestic supply chains. Capacity expansion remains constrained by specialized workforce shortages, with a 2025 BIO submission citing more than 60,000 unfilled U.S. biomanufacturing positions, alongside high labor, energy, water and compliance costs.[4]
M&A
M&A activity strengthened in Massachusetts in the first half of 2026: 11 companies were acquired for a reported $18.0 billion, compared with $7.6 billion at the same point in 2025. In August 2026, Xcellon Biologics also agreed to acquire NextCure’s 40,000-square-foot GMP facility to expand its integrated CRDMO platform.[14][15]
Regulation
In May 2026, the U.S. FDA issued immediate-implementation guidance on chemistry, manufacturing and controls flexibilities for cellular and gene-therapy products submitted for biologics licenses. In November 2026, FDA also issued final guidance recommending science- and risk-based potency controls across development, manufacturing and commercialization.[16]
Latest news
Genentech reached the structural-framework milestone for its $2 billion Holly Springs, North Carolina biomanufacturing facility in August 2026; the project is expected to support more than 500 high-wage manufacturing roles. Amgen separately announced $300 million of additional U.S. manufacturing investment in May 2026, bringing its announced U.S. manufacturing investment over the prior year to nearly $2 billion.[17][18]

02 Ranking

Top 10 Companies in the Biomanufacturing Industry

The leading companies in the biomanufacturing industry, ranked on market impact, performance, momentum, innovation and brand popularity.

Updated November 18, 2026 · Next review December 18, 2026

Verdict

Eli Lilly and Company stands out for large-molecule biologics manufacturing expansion because it is expanding manufacturing for monoclonal antibodies, bioconjugates and other large molecules, while Samsung Biologics focuses on commercial antibody manufacturing since Plants 1 through 4 support large-scale production for global customers.

Ranked by Overall score · How we score ↓

Editor's top 3 picks

Where to start, by need.

  1. #1 Overall · Leader in biologic manufacturing

    Eli Lilly and Company

    US

    Ranked #1 · 9.3 · Biologic manufacturing

    Why we picked it: It combines expansion in large-molecule manufacturing with an an operating margin of 40.4% and revenue growth of 44.7%.

  2. Leader in antibody CDMO

    Samsung Biologics

    KR

    Ranked #2 · 9.1 · Antibody CDMO

    Why we picked it: Its CDMO scale for commercial antibodies is paired with an an operating margin of 45.4% and revenue growth of 30.3%.

  3. Leader in vaccines manufacturing

    Serum Institute of India

    IN

    Ranked #3 · 9.1 · Vaccines manufacturing

    Why we picked it: Its vaccine manufacturing footprint aligns with an estimated 36% revenue growth.

Pick 1 is the #1 company overall. Picks 2 and 3 are the highest-ranked companies in the top 5 that add a new segment.

Full ranking

Sort by
Top 10 companies in the biomanufacturing industry, 2026 – Gitnux ranking
#CompanyOverall ↓Company snapshot
1

Eli Lilly and Company

Biologic manufacturing · US

9.3
2

Samsung Biologics

Antibody CDMO · KR

9.1
3

Serum Institute of India

Vaccines manufacturing · IN

9.1
4

Lonza

Biopharma CDMO · CH

9.0
5

Thermo Fisher Scientific

Biologics CDMO services · US

8.8
6

Roche

Branded biologics and diagnostics manufacturing · CH

8.8
7

Pfizer

Vaccines, biologics and gene-therapy manufacturing · US

8.4
8

Fujifilm

Biopharmaceutical CDMO through Fujifilm Diosynth · JP

8.3
9

AGC Biologics

Global biologics and advanced-therapy CDMO · US

8.1
10

Recipharm

Pharmaceutical and advanced-biologics CDMO · CH

7.7

How we score

  • Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
  • Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
  • Momentum (20%): growth trajectory and future potential.
  • Innovation (15%): R&D intensity and how technologically advanced the company is.

Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.

Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.

Cadence Recalculated when new figures are published; next review December 18, 2026.

Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.

Cite this ranking

APA

Samuel Norberg. (2026, November 18). Top 10 companies in the biomanufacturing industry. In Biomanufacturing Industry Statistics. Gitnux. https://gitnux.org/biomanufacturing-industry-statistics/#top-companies

report visual · Comparison

Biological product manufacturing employment by state (United States)

North Carolina leads with 6,816.

North Carolina6,816
New York6,252
Pennsylvania4,398
California3,087
Wisconsin2,782
Iowa2,728
source-verifiedbio.org

04 Statistics

Market Intelligence

We quantify 2025 market sizing across next-generation and digital biomanufacturing, including a $22.44 billion 2025 digital market and a $25.94 billion next-generation market estimate.

Market size, volume and shipments in the biomanufacturing industry

  • $25.94 billion was the estimated 2025 global next-generation biomanufacturing market, covering single-use systems, continuous bioprocessing, modular facilities and cell-free systems; revenue measure.[1]
  • $21.5 billion was the estimated 2024 global biomanufacturing market, covering biological production using living organisms, cells or biological systems; value measure, not physical volume.[2]
  • $22.44 billion was the estimated 2025 global digital biomanufacturing market, covering software, connected equipment and services used in biomanufacturing; revenue measure.[3]

Forecast growth and shipments in the biomanufacturing industry

  • The global next-generation biomanufacturing market was forecast to reach $60.85 billion by 2035, growing at 8.9% CAGR during 2026–2035; category covers single-use, continuous, modular and cell-free platforms.[1]
  • The global biomanufacturing market was forecast to reach $31.5 billion by 2030 from $21.5 billion in 2024, implying 6.6% CAGR; category covers biological production using living organisms, cells or biological systems.[2]
  • The global digital biomanufacturing market was forecast to reach $66.14 billion by 2034 from $25.16 billion in 2026, at 12.84% CAGR during 2026–2034; value measure.[3]

Company counts and size structure in the biomanufacturing industry

  • 46,936 workers were employed in U.S. biological product manufacturing in 2025, up 15.8% from 2021; the measure uses NAICS 325414 and covers biologic medicines except diagnostics.[4]
  • 78 U.S. biomanufacturing sites with toll capacity were listed in the BioP2P directory in April 2024; the directory covers facilities offering scale-up or commercial manufacturing capacity.[5]
  • 45 U.S. states had employment in biological product manufacturing in 2025, while 36 states had at least 50 jobs; the measure uses NAICS 325414.[4]

05 Statistics

Strategy & Growth

We compile 2024–2025 facility and investment announcements, plus modality expansion signals like Fujifilm Diosynth’s 160,000 litres of additional mammalian-cell bioreactor capacity.

Capacity expansion in the biomanufacturing industry

  • More than $26 billion in U.S. pharmaceutical and life-science manufacturing capital expenditure was pledged in 2025, including biomanufacturing facilities; the measure is announced investment, not commissioned capacity.[6]
  • Nearly $50 billion in U.S. biomanufacturing-facility announcements accumulated across 2024–2025, almost 80% more than announcements made during 2020–2023.[6]
  • Fujifilm Diosynth announced 160,000 litres of additional mammalian-cell bioreactor capacity at Holly Springs, North Carolina, with a $1.2 billion investment and production planned for 2028.[7]
  • A biomanufacturing facility expansion in Tuas Biomedical Park, Singapore, was reported to add 120,000 litres of bioreactor capacity through a $1.4 billion investment.[8]

06 Statistics

Production & Operations

We separate productive-asset counts from company counts, showing 1,556 biopharmaceutical manufacturing facilities across 48 U.S. states and Puerto Rico.

Installed base and productive capacity in biomanufacturing

  • 240 facilities and 140 companies were tracked for recombinant-protein bioproduction capacity serving U.S. and European markets in 2024.[9]
  • 1,556 biopharmaceutical manufacturing facilities operated across 48 U.S. states and Puerto Rico; the source uses facilities as the productive-asset count, not companies, in its latest reported snapshot.[10]
  • Nearly 20% of new U.S. biopharmaceutical manufacturing facilities produce active pharmaceutical ingredients, a capacity-use split within the 1,556-facility national base.[10]
  • 2,362 European biorefineries and 479 European pilot, demonstration and semi-industrial plants were identified across bioeconomy manufacturing categories using JRC 2023 and Pilots4U 2024 data.[11]

07 Statistics

People & Workforce

We connect headcount pressure to output constraints, including 46,936 workers employed in 2025 and more than 60,000 unfilled positions reported in the U.S.

Employment and hiring in the biomanufacturing industry

  • More than 60,000 positions were reported as unfilled in the U.S. biomanufacturing sector, including bioprocess-engineering and quality-assurance roles; the source does not provide a newer dated count.[4]
  • 46,936 U.S. biological-product-manufacturing workers were employed in 2025, up 15.8% from 2021; the measure corresponds to NAICS 325414 and is a focused biopharmaceutical-biomanufacturing proxy.[4]
  • 77% of U.S. biomanufacturing employment was concentrated in 12 states in 2025; the report defines the segment using NAICS 325414.[4]
  • 45 U.S. states reported biomanufacturing employment in 2025, while 36 states had at least 50 biomanufacturing jobs.[4]

08 Statistics

Pricing & Finance

We track cost drivers using labor and water intensity examples, including $75,000–$95,000 entry-level bioprocess-engineer salaries in the U.S. versus $15,000–$21,000 in China.

Capex and investment in the biomanufacturing industry

  • €60–200 million is the estimated investment range for smaller-scale, modular or specialised biotechnology production facilities in the European Union.[12]
  • €316–428 million is the estimated investment range for large-scale biotechnology manufacturing facilities in the European Union, covering facility construction and production infrastructure.[12]
  • $300 million was announced in May 2026 for Amgen’s expansion of a biologics manufacturing facility in Juncos, Puerto Rico, an example of U.S. biomanufacturing capital investment.[4]
  • Hundreds of billions of dollars were announced for U.S. biomanufacturing facilities over the 12 months to August 2026, with projects covering more than 17 million square feet and 30,000 projected jobs over five to seven years.[4]

Key questions about the biomanufacturing industry

How large is the U.S. biomanufacturing value added market?
The latest available NIST estimate puts U.S. biomanufacturing value added at $438.8 billion in 2021 economic activity.
What growth rate is expected for digital biomanufacturing through 2034?
The global digital-biomanufacturing market is projected to reach $66.14 billion by 2034 from $25.16 billion in 2026, implying a 12.84% CAGR from 2026 to 2034.
Which companies lead the biomanufacturing industry?
Eli Lilly and Company stands out for large-molecule biologics manufacturing expansion because it is expanding manufacturing for monoclonal antibodies, bioconjugates and other large molecules, while Samsung Biologics focuses on commercial antibody manufacturing since Plants 1 through 4 support large-scale production for global customers.
What technology shifts are most tied to near-term digital-biomanufacturing demand?
The digital segment includes manufacturing-execution software, automation, digital twins, analytics and related services, reflecting scale-up of digital and automation use in biomanufacturing.
How concentrated is U.S. biomanufacturing employment geographically?
In 2025, 77% of the 46,936 biological-product-manufacturing jobs were located in 12 states, even though 45 states reported employment in the sector.
Where do supply constraints show up in workforce and capacity signals?
More than 60,000 biomanufacturing positions were reported as unfilled in the U.S., and capacity expansion is described as constrained by specialized workforce shortages alongside high labor, energy, water and compliance costs.
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Samuel Norberg. (2026, November 18). Biomanufacturing Industry Statistics. Gitnux. https://gitnux.org/biomanufacturing-industry-statistics
MLA
Samuel Norberg. "Biomanufacturing Industry Statistics." Gitnux, 18 Nov 2026, https://gitnux.org/biomanufacturing-industry-statistics.
Chicago
Samuel Norberg. 2026. "Biomanufacturing Industry Statistics." Gitnux. https://gitnux.org/biomanufacturing-industry-statistics.